DUBLIN, March 26, 2024 /PRNewswire/ — The “Global Exosome Market: Size, Forecast, Trials, and Trends, 2023” report has been added to ResearchAndMarkets.com’s offering.
Exosome technologies have been developing rapidly in recent years and substantial growth is expected for the market as they get integrated into the fields of liquid biopsy, precision medicine, and regenerative medicine. In particular, cancer-derived exosomes influence the invasive potential of cells by regulating angiogenesis, metastasis, and immunity, making them an extremely useful source of biomarkers for use in cancer detection, diagnosis, and therapeutic selection.
The cargo contained within exosomes can offer prognostic information for a range of diseases – including cardiovascular, renal, neurodegenerative, and metabolic diseases – as well as cancer. Researchers investigating exosome biomarkers have discovered, identified, and reported the presence of hundreds of biomolecules within the lumen of exosomes. This discovery has compelled a rapid rise in exosome-related cancer biomarker research, including the use of exosomes for the detection, monitoring, and treatment of a diverse range of oncologic conditions.
Importantly, exosomes are present within a diverse range of biofluids, including serum, plasma, urine, seminal fluid, CSF, saliva, tears, and breast milk. For this reason, exosome-based diagnostics are minimally invasive, offering ease of use and speed of detection. Exosomes can also act as prognostic indicators and predictors of a patient’s response to a specific course of treatment.
Exosomes are also being explored for their use as cell-free therapeutics. For example, if a patient has a disease caused by a missing or defective protein or microRNA, the patient’s exosomes can be isolated, modified with the appropriate siRNA or protein, and injected back into the patient for treatment. Numerous approaches are being researched for creating drug-loaded exosomes and exosomes themselves can exert powerful effects. For example, mesenchymal stem cell (MSC) derived exosomes have the capacity to suppress inflammation, prevent scar tissue formation, and mediate a healthy immune response.
For these reasons, exosomes have gone from being overlooked to rapidly gaining momentum as a novel strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering cells to patients. Although exosomes were discovered more than 30 years ago, it was not until recently that the scientific community began to give credit to exosomes for a range of promising traits.
When exosome publications are analyzed, U.S. authors have published approximately 40% of the articles and China comes in second place. When the term “exosome” is searched in the scientific literature, Dr. Susanne Gabrielsson from the Karolinska Institutet in Sweden is the leading author. When the term “extracellular vesicles” is searched, Unicyte AG, a regenerative medicine unit of Fresenius Medical Care, takes the lead. Headquartered in Switzerland, the company has published more than 100 papers on exosomes and extracellular vesicles in combination with Professor Giovanni Camussi.
To date, three pharma companies (Takeda, Jazz Pharmaceuticals, and Roche Pharmaceutical Company) have signed partnership deals with exosome companies offering payment terms structured to deliver at or around $1 billion dollars. Within the past 5 years, there have been at least 7 partnership deals within the exosome industry, 8 large venture capital events, and 2 landmark acquisitions.
Globally, there are at least 204 clinical trials focusing on exosome-related studies. Of these, 114 trials are evaluating exosome-based therapeutics and 74 trials are testing exosome-based diagnostic tests. Currently, 93 of the exosome trials (45%) are observational studies and 111 of them (55%) are interventional studies. The exosome industry has also achieved two approvals of FDA-approved diagnostic tests: Bio-Techne’s ExoDx Prostate IntelliScore Test for prostate cancer and Guardant’s 360 CDx test for non-small cell lung cancer.
To characterize the rapidly expanding exosome market, the analyst has released a 312-page global market report that explores the growing demand for exosome therapeutics, diagnostics, research tools, and manufacturing technologies. The report reveals trend rate data for exosome patents, grants, scientific publications, and clinical trials. It highlights information about exosome industry partnerships, merger and acquisition (M&A) activity, and financing events. It features company profiles for 118 global competitors from across the exosome marketplace. Importantly, it presents market size determinations by market segment with forecasts through 2030.
Today the exosome industry is witnessing:
A surging number of scientific papers investigating exosomes and their applications
Rising numbers of clinical trials investigating exosome therapeutics and diagnostics
Swelling appetite among investors for exosome technology
An increasingly competitive IP environment
A diverse range of co-development partnerships
Proliferating numbers of exosome competitors in all major life science markets worldwide
Companies Mentioned
101 Bio
Abbexa
Abnova
Adipomics
Aegle Therapeutics
Aethlon Medical
AgeX Therapeutics
Ambiotech
AMS Biotechnology, Ltd. (AMSBIO)
Anjarium Biosciences
Antibodies-Online
Aposcience
Aruna Bio
ArunA Biomedical
Astellas
Avalon GloboCare Corp.
Aviva Systems Biology
Azymus Therapeutics
Beckman Coulter Life Sciences
Bio-Techne
BioCat GmbH
BioFluidica
Biological Dynamics
Biorbyt
BioRegenerative Sciences
BioVision
Boehringer Ingelheim
BrainStorm Cell Therapeutics
BreStem Therapeutics
Capricor Therapeutics
Carmine Therapeutics
CD Bioparticles
Cell Care Therapeutics
Cell Factory BVBA/Esperite
Cell Guidance Systems
Cellarcus Biosciences
CEVEC
Ciola
CK-Exogene
Clara Biotech
Codiak Biosciences
Coya Therapeutics
Craif
Creative Bioarray
Creative Biolabs
Creative Medical Technology Holdings
Creative Proteomics
CreativeBiostructure
Curexsys GmbH
CUSABIO TECHNOLOGY
Diadem Biotherapeutics
Direct Bio
DLdevelop
Eli Lilly
Entelexo Biotherapeutics
EverZom
Evomic Science
Evora Biosciences SAS
Evotec SE
Evox Therapeutics, Ltd.
ExBiome BV
Excella Bio
ExoCan Healthcare Technologies
ExoCoBio
Exocyte Therapeutics
Exogenus Therapeutics
ExoPERT
Exopharm Pty., Ltd.
Exosome Diagnostics, Inc (Bio-Techne)
Exosome Sciences
ExosomeDx (biotechne)
ExosomePlus
Exosomics
ExoVectory
Exrkine
Florica Therapeutics
Fresenius Medical Care
GenWay Biotech
HansaBioMed Lifesiences
ILIAS Biologics
Innocan Pharma
Innovex Therapeutics
INOVIQ
Intezyne
Invent Biotechnologies
Izon Science
Jazz Pharmaceuticals
Kimera Labs
La Trobe University
Leading Biology
LifeSpan Biosciences
Lonza Group
Mantra Bio
MDimune
Miltenyi Biotech
miR Scientific
Mursla
MyBioSource
NanoSomics
NanoSomiX
NanoView Biosciences
Navigo Proteins
NeurExo Sciences
NeuroDex
New England Peptide
Norgen Biotek
Novus Biologicals
nRix Dx
NurExone Biologic
Oasis Diagnostics
OmniSpirant
Organicell
Orgenesis
OriGene Technologies
Paracrine Therapeutics
PureTech Health
QIAGEN
Recipharms
ReNeuron
RION
Roche Pharmaceutical
RoosterBio
Rosetta Exosome
Sarepta Therapeutics
System Biosciences
Takeda
Tavec Pharma
Theoria Science
Thermo Fisher Scientific
TransGen Biotech
TriArm Therapeutics
UCI
Unicyte
United Therapeutics
Univercells Technologies
University of Adelaide
Versatope Therapeutics
Vesigen Therapeutics
VivaZome Therapeutics
Xollent Biotech
XOStem
YMAIR Genomics
For more information about this report visit https://www.researchandmarkets.com/r/y2q3a4
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets